{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:08:25Z","timestamp":1783609705505,"version":"3.55.0"},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2022,2,28]]},"DOI":"10.18632\/aging.203919","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T17:04:44Z","timestamp":1645895084000},"page":"1959-1982","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis"],"prefix":"10.18632","volume":"14","author":[{"given":"Shitong","family":"Lin","sequence":"first","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Peng","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canhui","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Gao","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhi","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wei","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Chu","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghan","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncheng","family":"Wei","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Ding","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.","volume":"7","author":"Bray","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1200\/JCO.1998.16.6.2133","article-title":"Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.","volume":"1","author":"Postmus","year":"1998","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.","volume":"33","author":"Davidson","year":"1996","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","article-title":"Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.","volume":"8","author":"Hortobagyi","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1006\/gyno.1996.0227","article-title":"A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.","volume":"6","author":"Mutch","year":"1996","journal-title":"Gynecol Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.1999.17.3.761","article-title":"Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.","volume":"1","author":"Dimopoulos","year":"1999","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.","volume":"1","author":"Ochiai","year":"2013","journal-title":"Lancet Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/annonc\/mdp401","article-title":"Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer.","volume":"2","author":"Nukiwa","year":"2010","journal-title":"Ann Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.2007.13.1912","article-title":"Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.","volume":"2","author":"Tester","year":"2008","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.","volume":"1","author":"Dobelbower","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.","volume":"1","author":"Goldstein","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","article-title":"NCCN Guidelines Insights: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.","volume":"1","author":"Khan","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10549-010-1000-2","article-title":"Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.","volume":"12","author":"Ouyang","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"14","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.","volume":"39","author":"Sundar","year":"2019","journal-title":"Lancet"},{"key":"15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ctrv.2011.10.008","article-title":"Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis.","volume":"3","author":"Campbell","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","article-title":"Theoretical concepts and the emerging role of taxanes in adjuvant therapy.","volume":"6","author":"Norton","year":"2001","journal-title":"Oncologist"},{"key":"17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2004.04.004","article-title":"Dose-dense chemotherapy in breast cancer and lymphoma.","volume":"3","author":"Schmitz","year":"2004","journal-title":"Semin Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/tbj.12364","article-title":"The development of dose-dense adjuvant chemotherapy.","volume":"2","author":"Dang","year":"2015","journal-title":"Breast J"},{"key":"19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.","volume":"4","author":"Par\u00f6","year":"2002","journal-title":"Acta Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.","volume":"37","author":"Boente","year":"2016","journal-title":"N Engl J Med"},{"key":"21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.","volume":"1","author":"Cavazzini","year":"2014","journal-title":"Lancet Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","article-title":"Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.","volume":"2","author":"Frye","year":"2005","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1634\/theoncologist.2012-0057","article-title":"Weekly paclitaxel\/carboplatin\/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.","volume":"1","author":"Shao","year":"2013","journal-title":"Oncologist"},{"key":"24","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer.","volume":"35","author":"Davidson","year":"2008","journal-title":"N Engl J Med"},{"key":"25","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.","volume":"2","author":"Hudis","year":"2008","journal-title":"J Clin Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3816\/CBC.2005.n.047","article-title":"Two concurrent phase II trials of paclitaxel\/carboplatin\/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.","volume":"6","author":"Jenkins","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4103\/sajc.sajc_18_17","article-title":"Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study.","volume":"7","author":"Malhotra","year":"2018","journal-title":"South Asian J Cancer"},{"key":"28","doi-asserted-by":"publisher","first-page":"ix80","DOI":"10.1093\/annonc\/mdv525.04","article-title":"270PD An open label randomized phase 2, study of weekly vs 3 weekly paclitaxel and carboplatin in stage IVB or recurrent carcinoma cervix.","volume":"2","author":"Kumar","year":"2015","journal-title":"Ann Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/annonc\/mdn745","article-title":"A randomized, phase II trial of two dose schedules of carboplatin\/paclitaxel\/cetuximab in stage IIIB\/IV non-small-cell lung cancer (NSCLC).","volume":"2","author":"Stella","year":"2009","journal-title":"Ann Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/annonc\/mdl344","article-title":"Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.","volume":"1","author":"Obasaju","year":"2007","journal-title":"Ann Oncol"},{"key":"31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/annonc\/mdj016","article-title":"A randomized phase II trial comparing every 3-weeks carboplatin\/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.","volume":"1","author":"Niell","year":"2006","journal-title":"Ann Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3816\/clc.2006.n.016","article-title":"Multicenter randomized trial for stage IIIB\/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel\/carboplatin.","volume":"7","author":"Ukena","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.critrevonc.2018.02.016","article-title":"Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials.","volume":"12","author":"Benedetti Panici","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"34","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"34","author":"Peters","year":"2011","journal-title":"BMJ"},{"key":"35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/jrsm.1468","article-title":"Investigating and dealing with publication bias and other reporting biases in meta-analyses of health research: A review.","volume":"1","author":"Egger","year":"2021","journal-title":"Res Synth Methods"},{"key":"36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.","volume":"32","author":"Smith","year":"2001","journal-title":"BMJ"},{"key":"37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","article-title":"Progress in research on paclitaxel and tumor immunotherapy.","volume":"2","author":"Chen","year":"2019","journal-title":"Cell Mol Biol Lett"},{"key":"38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/bs.podrm.2018.11.001","article-title":"Paclitaxel.","volume":"4","author":"AlQuadeib","year":"2019","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1089\/152581602753448577","article-title":"Docetaxel versus paclitaxel for antiangiogenesis.","volume":"1","author":"Dammacco","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"key":"40","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/jnci\/88.18.1308","article-title":"Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.","volume":"8","author":"Milas","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1089\/cbr.1999.14.31","article-title":"Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.","volume":"1","author":"Cheung","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"42","first-page":"3776","article-title":"Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.","volume":"5","author":"Jain","year":"1999","journal-title":"Cancer Res"},{"key":"43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00685842","article-title":"Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.","volume":"3","author":"Bhuyan","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"44","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.","volume":"6","author":"Folkman","year":"2000","journal-title":"Cancer Res"},{"key":"45","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.lungcan.2011.12.001","article-title":"A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.","volume":"7","author":"Shi","year":"2012","journal-title":"Lung Cancer"},{"key":"46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ctrv.2009.10.006","article-title":"Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.","volume":"3","author":"Polyzos","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":"Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.","volume":"1","author":"Schuetz","year":"2002","journal-title":"Pharmacogenetics"},{"key":"48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.","volume":"1","author":"Goldstein","year":"2001","journal-title":"Pharmacogenetics"},{"key":"49","article-title":"Mantle Cell Lymphoma.","author":"Acharya","year":"2022","journal-title":"StatPearls"},{"key":"50","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1159\/000508516","article-title":"Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.","volume":"9","author":"Graziano","year":"2020","journal-title":"Oncology"},{"key":"51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2011.09.028","article-title":"An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.","volume":"12","author":"Chan","year":"2012","journal-title":"Gynecol Oncol"},{"key":"52","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2165\/10899510-000000000-00000","article-title":"An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.","volume":"2","author":"Jones","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"53","doi-asserted-by":"publisher","first-page":"SP46","DOI":"10.37765\/ajmc.2021.88563","article-title":"Cost of home vs clinic administration of paclitaxel in metastatic breast cancer.","volume":"2","author":"Dokubo","year":"2021","journal-title":"Am J Manag Care"},{"key":"54","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"33","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"55","doi-asserted-by":"publisher","first-page":"58709","DOI":"10.18632\/oncotarget.11094","article-title":"Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.","volume":"7","author":"Benedetti Panici","year":"2016","journal-title":"Oncotarget"},{"key":"56","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"34","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"Sydes","year":"2007","journal-title":"Trials"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T17:42:05Z","timestamp":1646674925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2,28]]}},"alternative-id":["203919","35218640"],"URL":"https:\/\/doi.org\/10.18632\/aging.203919","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,26]]}}}